The TreatFTD Fund
The Treat FTD Fund was launched in 2016 with the Alzheimer’s Drug Discovery Foundation to support clinical trials testing novel or repurposed drugs for FTD disorders. Running clinical trials in FTD patients will enable investigators to identify optimal approaches to targeting this unique patient population. In addition, trials supported through the Treat FTD Fund will complement efforts such as the FTD Biomarkers initiative and the Accelerating Drug Discovery for FTD program by employing emergent advances in biomarker development and preclinical research.
Guidelines for Proposed Trials
- Should include both genetic and sporadic forms of any FTD disorder.
- Application must include clear description of rationale for the mechanism of action in the targeted population.
- Roughly 70% of FTD disorders occur sporadically. While applications utilizing gene therapy approaches are of interest, applications that target mechanisms that may contribute to sporadic FTD are encouraged.
- Agnostic to drug target.
- Symptomatic or disease-modifying.
- Novel as well as repurposed therapies.
Outside the scope of this program: Behavioral/social interventions or lifestyle modifications.
- Clinical proof of concept studies.
- Pilot proof-of-mechanism studies.
- Phase 0/1 studies in healthy volunteers assessing pharmacodynamic outcomes.
- Innovative trial designs, exploratory endpoints, and/or multidomain biomarkers that define specific subpopulations are encouraged.
Outside the scope of this program: Studies designed to solely test safety in healthy volunteers.
- Utilization of existing resources, clinical coordination networks, and patient registries highly encouraged. See current RFP for links to relevant resources.
- Duration: 1 – 3 years with potential for follow-on funding.
- Amount of award (USD): $500,000 – $2 million. Leveraging other sources of funding encouraged.
- Application of funds: Direct costs only.
Who can apply?
Researchers and clinicians in the U.S. and worldwide working in:
- Academic medical centers and universities or non-profits; industry partnerships strongly encouraged
- Biotechnology companies (existing as well as new spin-offs) that demonstrate a clear need for non-profit funding
Timeline: 2019 Awards
- September 2018: RFP posted
- November 9, 2018: LOIs due
- February 15, 2019: Invited full proposals due
Applications should include:
- Confirmation of drug supply
- IRB-ready clinical trial protocol
- Explicit plan for data sharing and/or making trial results publicly available
Applications are reviewed by a Joint Steering Committee appointed by AFTD and ADDF. Applications from biotechnology companies will also be reviewed by ADDF’s Business Advisory Board.
Click here to view the RFP and access the application portal.
For program-related inquiries, please contact:
- Lauren Friedman, PhD, Acting Director for Scientific Affairs, ADDF
- Nadine Tatton, PhD, Scientific Director, AFTD
Phone: 267-758-8644 / Email: email@example.com
For application submission inquiries, please contact:
- Grants and Mission-Related Investments Team